Hiring in biotech breaks down when speed is prioritized without clarity. Job descriptions describe tasks, not how decisions are made under pressure, how roles evolve in lean teams, or what actually defines success.
Our new whitepaper reveals how innovative rare disease, cell and gene therapy companies are turning to the strategic deployment of fractional leadership in response to the challenging fundraising environment.
This white paper explores how the absence of senior talent impacts every stage of asset development, from early clinical strategy through regulatory readiness and commercial planning.
Every day without critical leadership puts your development timelines at risk. Each vacant VP of Clinical Operations pushes trial timelines further into the future. Empty regulatory roles stall FDA engagement. Gaps in commercial leadership can cost you substantial portions of projected revenue.
